Direct medical costs of COPD – An excess cost approach based on two population-based studies

Menn, Petra; Heinrich, Joachim; Huber, Rudolf M.; Jörres, Rudolf A.; John, Jürgen; Karrasch, Stefan; Peters, Annette; Schulz, Holger; Holle, Rolf

doi:10.1016/j.rmed.2011.10.013

Cited by 55 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Th e burden of COPD on the health care sector is substantial and has been described and documented in previous cost-of-illness studies concentrating on treatment of COPD and not considering co-morbidity (13)(14)(15)(16)(17)(18)(19)(20). Furthermore, the information and assumption of costs have focused on direct costs because indirect costs have generally not been available.…”

Section: Introductionmentioning

confidence: 99%

Economic and Health Consequences of COPD Patients and Their Spouses in Denmark—1998–2010

Løkke

Hilberg

Kjellberg

et al. 2013

COPD

View full text Add to dashboard Cite

This study provides unique data on the economic consequences of COPD patients in Denmark and their spouses as well as displaying the serious health consequences for the individual spouse and society. Second, data shows substantial impact of COPD on income level and health expenses regardless of age and gender. It could be speculated that early identification and intervention might contribute to more health and economic equality between patients and controls.

show abstract

Section: Introductionmentioning

confidence: 99%

Economic and Health Consequences of COPD Patients and Their Spouses in Denmark—1998–2010

Løkke

Hilberg

Kjellberg

et al. 2013

COPD

View full text Add to dashboard Cite

show abstract

“…C hronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality in Europe and a major consumer of resources in both primary and secondary healthcare [1,2]. The disease has an increasingly high profile with health authorities, health insurance companies and healthcare providers.…”

mentioning

confidence: 99%

European COPD Audit: design, organisation of work and methodology

et al. 2012

View full text Add to dashboard Cite

Clinical audit has an important role as an indicator of the clinical practice in a given community. The European Respiratory Society (ERS) chronic obstructive pulmonary disease (COPD) audit was designed as a pilot study to evaluate clinical practice variability as well as clinical and organisational factors related to outcomes for COPD hospital admissions across Europe.The study was designed as a prospective observational noninterventional cohort trial, in which 422 hospitals from 13 European countries participated. There were two databases: one for hospital's resources and organisation and one for clinical information.The study was comprised of an initial 8-week phase during which all consecutive cases admitted to hospital due to an exacerbation of COPD were identified and information on clinical practice was gathered. During the 90-day second phase, mortality and readmissions were recorded. Patient data were anonymised and encrypted through a multi-lingual web-tool. As there is no pan-European Ethics Committee for audits, all partners accepted the general ethical rules of the ERS and ensured compliance with their own national ethical requirements. This paper describes the methodological issues encountered in organising and delivering a multi-national European audit, highlighting goals, barriers and achievements, and provides valuable information for those interested in developing clinical audits.

show abstract

“…Deutsche Quellen nennen 6585 € pro Jahr bei schwerer COPD [34,198]. Eine Studie, die allerdings nur die direkten medizinischen Kosten betrachtete, kam in zwei bevölke-rungsbezogenen epidemiologischen Ansätzen in Süddeutschland auf Kosten in Höhe von 2812 € pro Patient und Jahr (Schweregrad ≥ 2 nach GOLD) [199]. Rauchen ist ein erheblicher Risikofaktor für Frühberentung unter der Diagnose "COPD" (OR 22,0; 95 % KI 10,0 -48,5) [200].…”

Section: Gesundheitsökonomische Aspekteunclassified

Tabakentwöhnung bei COPD

et al. 2014

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. Cigarette smoking is the main cause of COPD. Quitting smoking is thus the most effective treatment strategy and central in COPD prevention. A number of guidelines on prevention, diagnosis, therapy and rehabilitation of COPD have been published. To help implementing and standardizing smoking cessation in COPD a guideline was published 2008 in Germany focusing on this complex issue. The present guideline is an update of the 2008 guideline and has a high grade of evidence (S3 according to the AWMF; Arbeitsgemeinschaft wissenschaftlicher medizinischer Fachgesellschaften). The guideline gives comprehensive and practical information on how to integrate smoking cessation as an central part of COPD therapy.

show abstract

Direct medical costs of COPD – An excess cost approach based on two population-based studies

Abstract: The finding that utilization and costs are considerably higher in moderate but not in mild COPD highlights the economic importance of prevention and of interventions aiming at early diagnosis and delayed disease progression.

Cited by 55 publications

References 36 publications

Economic and Health Consequences of COPD Patients and Their Spouses in Denmark—1998–2010

Economic and Health Consequences of COPD Patients and Their Spouses in Denmark—1998–2010

European COPD Audit: design, organisation of work and methodology

Tabakentwöhnung bei COPD

Contact Info

Product

Resources

About